Despite high awareness of AI and ML tools, some biopharma leaders may overlook opportunities to use automation as they take their programs to market. Inside this report, we’ll explore those potentially untapped areas as we unpack IPM.ai's latest survey results in the context of what’s next in a new era of AI-supported launch planning.
As more consumers embrace self-service as part of everyday life, it makes sense that patients would want that same experience from a hub program. How do your patient access and support services plan to evolve?
Biopharma organizations are exploring artificial intelligence across multiple use cases: patient identification, data analysis, regulatory submissions, and beyond. Along the way, they’re seeing both short- and long-term success; some changes are fast, and others are slow.
Pharma companies traditionally rely on payer coverage data, including formularies and restrictions, to understand the contours of their market access barriers. While these inputs are certainly valuable, they can create an incomplete picture. That’s why manufacturers are increasingly relying on real-world data (RWD) to uncover the blind spots in their market access analysis.
As healthcare in the US continues to decentralize, pharmacists can prepare for delivering more equitable care to patients in their community.
Precision medicine has been given ambitious descriptors: a miracle, a marvel, even a panacea. Consumers are plugging into the hype, with a recent survey commissioned by Wolters Kluwer finding that 68% of Americans believe their own DNA could help guide their providers’ prescription decisions. But at the other end of those hopeful expectations are the sobering realities of genomic innovations that haven’t yet found sweeping success.
Precision medicine is poised to impact consumers’ medications. What should pharmacists and clinicians understand about the impact of both genetics and social determinants before giving a prescription?
For rare disease trials, which are already challenging to enroll, the new guidance introduces nuances that speak to broader recruitment trends in orphan drugs. Here's what sponsors should know when approaching "rarified" rare disease protocols.
The awareness, investments, and enthusiasm surrounding vaccine research is at an all-time high. At the same time, challenges in pushing vaccine trials forward remain, and many barriers are more palpable now than ever before.
How biopharma companies can preempt threats to copay assistance with a more comprehensive approach to patient support.
BioPharma companies utilizing patient support hubs that offer wrap-around care have seen dramatic increases in access, affordability and adherence. What used to involve simple patient assistance and therapy access has evolved into dynamic systems that track, anticipate and offer resources to patients.
Health systems have an opportunity to partner with community health centers to reduce medical mistrust among historically marginalized groups, impacting health outcomes and equity.
To improve health equity, clinicians need to develop, showcase, and implement clinical empathy in their care delivery to help rebuild decades of medical mistrust among marginalized groups.
With protected health information (PHI) dispersed across wearables, apps, portals, and other places, more companies than ever have access to sensitive data, and that access comes with serious responsibilities. But businesses need to use data, so this creates a tension – a push and pull between access and security. As organizations attempt to make data less vulnerable, they may also make it less usable. And what good is that?
While the clinical research industry has taken steps toward more diversity, equity, and inclusion (DEI) within research and development, the gains should be taken in the context of the systemic barriers that remain. Despite stakeholders becoming more intentional and determined about trial diversity and FDA guidance to make trials more representative, there is more to be done to put R&D to work for everyone.